Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
Top Medical Stocks To Keep An Eye On – October 31st
01:35am, Sunday, 02'nd Nov 2025
Eli Lilly and Company, Pfizer, and UnitedHealth Group are the three Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of publicly traded companies
Top 15 High-Growth Dividend Stocks For November 2025
11:00pm, Saturday, 01'st Nov 2025
The Top 15 High-Growth Dividend Stock list for November 2025 offers a 1.39% yield and 19.88% five-year dividend growth. Despite underperforming SPY and VIG in October, the watchlist targets a long-ter
S&P 500 Giants JPMorgan, Eli Lilly Lead Five Stocks Near Buy Points
08:00am, Saturday, 01'st Nov 2025
Three S&P 500 components, including JPMorgan Chase and Eli Lilly, are among five stocks near buy points.
Medical Stocks To Watch Now – October 30th
05:47am, Saturday, 01'st Nov 2025
Eli Lilly and Company, UnitedHealth Group, and Pfizer are the three Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of publicly traded companies
Eli Lilly Seen In 'Pole Position' For Growth, Analysts Say
02:46pm, Friday, 31'st Oct 2025
Eli Lilly and Co. (NYSE:LLY) reported better-than-expected third-quarter earnings on Thursday and boosted its annual forecast, sending the stock higher.
Eli Lilly Has A Solid Upside Now After Its Q3 Earnings
10:52am, Friday, 31'st Oct 2025
Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin analogs. LLY posted a 54% YoY revenue jump and a 19% EPS beat, with managemen
Eli Lilly's obesity and diabetes treatments fuel growth and spark bidding war
10:11am, Friday, 31'st Oct 2025
The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker.
Lilly's quarterly results Thursday, combined with Novo Nordisk's unsolicited offer for a startup, confirm the $72 billion anti-obesity market is among pharma's hottest.
Eli Lilly: The Price Upside Just Increased
04:58pm, Thursday, 30'th Oct 2025
Eli Lilly delivered robust Q3 2025 results and guidance for non-GAAP EPS for the second consecutive quarter. When I last checked on the stock, there was still 20% upside to LLY for the remainder of 20
Eli Lilly and Company (LLY) Q3 2025 Earnings Call Transcript
02:46pm, Thursday, 30'th Oct 2025
Eli Lilly and Company ( LLY ) Q3 2025 Earnings Call October 30, 2025 10:00 AM EDT Company Participants Mike Czapar - Director of Investor Relations David Ricks - Chairman, CEO & President Lucas Montar
Lilly Beats on Q3 Earnings, Ups View, Mounjaro, Zepbound Drive Sales
02:01pm, Thursday, 30'th Oct 2025
Lilly tops Q3 estimates as Mounjaro and Zepbound fuel a 54% revenue surge, prompting the drugmaker to raise its full-year sales and earnings outlook.
Compared to Estimates, Lilly (LLY) Q3 Earnings: A Look at Key Metrics
11:30am, Thursday, 30'th Oct 2025
The headline numbers for Lilly (LLY) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimat
Eli Lilly Boosts Its Outlook on High Demand for Popular Weight-Loss Drugs
11:25am, Thursday, 30'th Oct 2025
Strong sales of Eli Lilly's weight-loss treatments Mounjaro and Zepbound helped power strong quarterly earnings, and the drugmaker boosted its outlook.
Eli Lilly CEO: Seeing global demand for weight loss drug Mounjaro
10:13am, Thursday, 30'th Oct 2025
Eli Lilly chairman and CEO David Ricks joins CNBC's “Squawk on the Street” team to discuss its quarterly earnings report that beat estimates, weight loss drug demand, its drug pipeline and more.
Mounjaro And Zepbound Power Eli Lilly's 54% Revenue Jump In Q3, Hikes 2025 Forecast
10:05am, Thursday, 30'th Oct 2025
Eli Lilly and Co. (NYSE:LLY) on Thursday reported better-than-expected third-quarter earnings and boosted its annual forecast, sending the stock higher.
